Literature DB >> 15680223

The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity.

D Allan Butterfield1, Debra Boyd-Kimball.   

Abstract

Amyloid beta-peptide (1-42) [Abeta(1-42)] has been proposed to play a central role in the pathogenesis of Alzheimer's disease, a neurodegenerative disorder associated with cognitive decline and aging. AD brain is under extensive oxidative stress, and Abeta(1-42) has been shown to induce protein oxidation, lipid peroxidation, and reactive oxygen species formation in neurons and synaptosomes, all of which are inhibited by the antioxidant vitamin E. Additional studies have shown that Abeta(1-42) induces oxidative stress when expressed in vivo in Caenorhabditis elegans, but when methionine 35 is replaced by cysteine, the oxidative stress is attenuated. This finding coupled with in vitro studies using mutant peptides have demonstrated a critical role for methionine 35 in the oxidative stress and neurotoxic properties of Abeta(1-42). In this review, we discuss the role of methionine 35 in the oxidative stress and neurotoxicity induced by Abeta(1-42) and the implications of these findings in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15680223     DOI: 10.1016/j.bbapap.2004.10.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  65 in total

1.  Sesaminol glucosides protect β-amyloid induced apoptotic cell death by regulating redox system in SK-N-SH cells.

Authors:  Min Young Um; Ji Yun Ahn; Mi Kyung Kim; Tae Youl Ha
Journal:  Neurochem Res       Date:  2011-12-06       Impact factor: 3.996

2.  Despite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicity.

Authors:  Panchanan Maiti; Aleksey Lomakin; George B Benedek; Gal Bitan
Journal:  J Neurochem       Date:  2010-03-20       Impact factor: 5.372

3.  Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.

Authors:  Yu-Fang Cheng; Chuang Wang; Huan-Bing Lin; Yun-Feng Li; Ying Huang; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2010-07-17       Impact factor: 4.530

Review 4.  From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.

Authors:  William A Banks
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

Review 5.  Actin dynamics and cofilin-actin rods in alzheimer disease.

Authors:  James R Bamburg; Barbara W Bernstein
Journal:  Cytoskeleton (Hoboken)       Date:  2016-03-01

Review 6.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

7.  Solvent-free MALDI-MS for the analysis of beta-amyloid peptides via the mini-ball mill approach: qualitative and quantitative advances.

Authors:  Sarah Trimpin; Max L Deinzer
Journal:  J Am Soc Mass Spectrom       Date:  2007-04-29       Impact factor: 3.109

Review 8.  Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment.

Authors:  Rukhsana Sultana; D Allan Butterfield
Journal:  J Bioenerg Biomembr       Date:  2009-10       Impact factor: 2.945

9.  Oxidative stress in the progression of Alzheimer disease in the frontal cortex.

Authors:  Mubeen A Ansari; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2010-02       Impact factor: 3.685

Review 10.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.